Study of PCUR-101 in Combination With ADT in Patients With mCRPC
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is an open label, non-randomized, Phase I, dose escalation/dose expansion study in
cohorts of patients with metastatic CRPC at Screening. Dose escalation uses a 3+3 design to
determine the maximum tolerated dose (MTD). Once the MTD is defined, the dose expansion phase
is used to define the recommended phase 2 dose.